|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | C07K 14/51 | (2006.01) |
| A61K 38/10 | (2006.01) | ||
| A61K 38/17 | (2006.01) |
| (11) | Number of the document | 2325199 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10014362.7 |
| Date of filing the European patent application | 2006-04-28 | |
| (97) | Date of publication of the European application | 2011-05-25 |
| (45) | Date of publication and mention of the grant of the patent | 2015-03-04 |
| (46) | Date of publication of the claims translation | 2015-09-25 |
| (30) | Number | Date | Country code |
| 677583 P | 2005-05-03 | US | |
| 776847 P | 2006-02-24 | US | |
| 782244 P | 2006-03-13 | US | |
| 792645 P | 2006-04-17 | US | |
| 411003 | 2006-04-25 | US |
| (72) |
Paszty, Christopher, US
Robinson, Martyn Kim, GB
Graham, Kevin, US
Henry, Alistair James, GB
Hoffmann, Kelly Sue, US
Latham, John, US
Lawson, Alastair, GB
Lu, Hsieng Sen, US
Winters, Aaron George, US
Winkler, David, US
Shen, Wenyan, US
Popplewell, Andy, GB
|
| (73) |
AMGEN, INC.,
One Amgen Center Drive, Thousand Oaks, CA 91320,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Sklerostiną surišantys agentai |
| Sclerostin binding agents |
| Payment date | Validity (years) | Amount | |
| 2021-03-22 | 16 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2021-11-23 |